Bronchiectasis Research Into Leukocyte biology and Lung Infections to Accelerate New Therapies (BRILLIANT)

niversity of Dundee0 sites80 target enrollmentApril 27, 2023

Overview

No summary available.

Registry

who.int

Start Date

April 27, 2023

End Date

July 1, 2025

Last Updated

last year

Study Type

Observational

Sex

All

Sponsor

niversity of Dundee

•Bronchiectasis cohort:
•1\. Age \>18 years
•2\. Bronchiectasis diagnosed by CT scan
•3\. Symptoms consistent with bronchiectasis: cough, sputum and/or frequent respiratory tract infections
•4\. Clinically stable defined by the absence of antibiotic therapy in the previous 4 weeks
•Healthy control cohort:
•1\. Age \>18 years

•Bronchiectasis cohort:
•1\. A primary diagnosis of asthma or COPD (secondary diagnoses and individuals with historical misdiagnosis will be permitted)
•2\. Immunodeficiency requiring immunoglobulin replacement therapy
•3\. Active allergic bronchopulmonary aspergillosis (defined by receipt of oral corticosteroids or anti\-fungal therapy)
•4\. Active tuberculosis
•5\. Traction bronchiectasis due to interstitial lung disease
•6\. Active SARS\-CoV\-2 infection or contact with a confirmed case in the previous 14 days
•7\. Active malignancy excluding non\-melanoma skin cancer
•8\. Antibiotic treatment for an acute respiratory tract infection or exacerbation in the previous 4 weeks
•9\. Treatment with anticoagulants